Cemiplimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and NICE (England), among others, recommended or restricted cemiplimab, while AWMSG (Wales) did not recommend it.
NYE METODER (Norway) has been easier on cemiplimab than on its own caseload: it refused 0 of 6 decisive submissions here (0%), against a base rate of 37% across everything it has assessed.
Assessment has run over 7.4 years, from 22 Feb 2019 at AWMSG (Wales) to 9 Jul 2026 at NICE (England).
DMC (Denmark) changed its position: not recommended on 25 Mar 2026, recommended by 1 Jun 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for cemiplimab, 2 submissions were never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 25 of 55 records date from 2023 or later.
The programme is broad: 14 distinct indication wordings are recorded for cemiplimab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 55 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess cemiplimab, on 22 Feb 2019; DMC (Denmark) did not open a file until 1 Feb 2024 — a wide spread of 5 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
10 of the 13 agencies here assessed cemiplimab more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
cemiplimab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for cemiplimab reads 24 recommended, 10 not recommended, 4 restricted and 4 no benefit, with 13 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 17 Jun 2026 | Indicaciones terapéuticas autorizadas: Carcinoma cutáneo de células escamosas LIBTAYO en monoterapia está indicado para … | not financed by the SNS · art. 92 d | source |
| NICE (England) | 16 Jun 2026 | NICE TA1165 | published appraisal | source |
| G-BA (Germany) | 4 Jun 2026 | Libtayo — benefit assessment §35a | added benefit: non-quantifiable (indication) | source |
| DMC (Denmark) | 1 Jun 2026 | Uhelbredelig ikke-småcellet lungekræft med PD-L1-ekspression > 50 % | Anbefalet | source |
| NYE METODER (Norway) | 18 Jan 2026 | Adjuvant behandling av voksne med kutant plateepitelkarsinom (CSCC) med høy risiko for tilbakefall etter kirurgi og strå… | introduced | source |
50 further decisions for cemiplimab, across 13 agencies, are not shown here. They include the most recent record on file, 9 Jul 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 39 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 55 decisions for cemiplimab from 13 agencies, 2019 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.